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I read with interest the report by Mortensen and coworkers
[1], who found the use of initial empiric antimicrobial therapy
with a β-lactam and a fluoroquinolone to be associated with
increased short-term mortality in patients with severe
community-acquired pneumonia (CAP) compared with other
guideline-concordant antimicrobial regimens. However, the
study has a number of limitations other than those stated by
the authors.
First and foremost, almost 51% of the patients had a PORT
(Pneumonia Patient Outcomes Research Team) score of 1–4
and did not meet the inclusion criteria as specified by the
authors. Second, almost 9% of the patients received
antibiotics after 8 hours, which alone is known to influence
outcomes in patients with pneumonia. Two large studies
showed that antibiotic administration within 4 hours [2] and
8 hours [3] of arrival in the hospital was associated with
decreased mortality and length of stay. It is possible that this
group of patients who received treatment after 8 hours was
composed entirely of those who received fluoroquinolones,
thus accounting for the adverse outcomes with this treatment.
Another important point pertains to the choice of antibiotic;
almost 25% of the patients in the study received
piperacillin–tazobactam for CAP. This treatment should be
reserved for serious hospital-acquired infections, and routinely
is not necessary for management of CAP except in situations
where Pseudomonas aeruginosa infection is suspected [4].
Using inappropriate antibiotics in such situations has
increased the incidence of expanded-spectrum β-lactamases,
which are resistant to multiple classes of antibiotics [5].
Finally, the results of this retrospective study are discordant
with the recently published MOXIRAPID study [6]. This multi-
center trial, conducted among adult patients hospitalized with
CAP, compared fluoroquinolone monotherapy (moxifloxacin)
with standard therapy (cephalosporin with or without a
macrolide). Although the clinical outcomes were similar in the
groups, patients randomly assigned to receive moxifloxacin
had rapid resolution of fever and relief of symptoms such as
chest pain, as recorded in patient diary entries.
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Authors’ response
EM Mortensen, MI Restrepo, A Anzueto and J Pugh
We appreciate Dr Agarwal’s interest in our article. However,
we should like to respond to the comments made.
First, the statement that 51% of patients had pneumonia
severity index scores of I–IV and therefore did not meet the
inclusion criteria is incorrect. As described in the Methods
section of our paper [1], the inclusion criterion for severe CAP
was either being in pneumonia severity index class V, meeting
American Thoracic Society criteria for severe pneumonia [4], or
being hospitalized in the intensive care unit (ICU) during the
first 24 hours after presentation. Although the pneumonia
severity index has been demonstrated to be the best risk
adjustment tool for CAP [7], it was designed to help determine
which patients may be treated as outpatients, and not which
patients should be admitted to the ICU [8]. Therefore we used
it only as one of several definitions of severe CAP. Our study
also points out the limitation of the pneumonia severity index in
identifying those patients who require ICU care.
Second, Dr Agarwal expresses concern that prolonged time
to initial receipt of antibiotics (>8 hours) might have co-
occurred with use of fluoroquinolones. As stated in the
Methods section of our report, a dichotomized variable of
whether or not a patient received an initial dose of antibiotics
within the currently recommended 4 hours was included in
our multivariable model. Also, as shown in Table 2 of thePage 2 of 2
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report, there were no significant differences with respect to
initial receipt of antibiotics within 4 hours between the
different antibiotics, and neither was there a significant
difference between antibiotic groups in administration within
8 hours (59% versus 56%; P = 0.72).
Third, Dr Agarwal criticizes the use of pipericillin–tazobactam as
part of the initial antimicrobial treatment in 25% of the patients
included in our cohort. According to the clinical practice
guidelines published by the Infectious Diseases Society of
America and the American Thoracic Society [4,9], the use of
these antimicrobials is part of the recommended regimens for
those with severe CAP, especially those who have a history of
structural lung disease, who are nursing home residents, or who
are at risk for Pseudomonas aeruginosa. Because 31% of our
patients had a history of chronic obstructive pulmonary disease
and 10% were from a nursing home, we consider usage of this
regimen to be quite appropriate.
Finally, regarding the recent MOXIRAPID study [6], that study
is not comparable to ours. First, the MOXIRAPID study
enrolled hospitalized patients with CAP without severe
disease. The mortality rate was 3% as compared with about
30–40% for previous studies of severe CAP [1,10,11]. Only
four patients included in that study had a pneumonia severity
index class V, and no information on the number of patients
who met American Thoracic Society criteria for severe
pneumonia [4] or the number of patients who required ICU
admission was provided. Therefore, it is highly unlikely that
this population included a significant number of patients with
severe pneumonia. In addition, the MOXIRAPID study
primarily compared antibiotic regimens that are not
considered guideline-concordant for severe CAP, and
nowhere in the report presenting the results of the study [6]
can we find separate information on the patients who were
treated with erythromycin and ceftriaxone (which would be
the only guideline-concordant regimen for severe CAP
studied). Also, nowhere in the literature could we find any
reports indicating that more rapid resolution of fever is
associated with improved outcomes for patients with CAP.
Therefore, although the MOXIRAPID study is an important
addition to the literature regarding care for patients
hospitalized with CAP who have low mortality rates, it bears
no relation at all to the findings of our study.
These views are those of the authors (EMM, MIR, AA and JP)
and do not necessarily represent the views of the Department
of Veterans Affairs (South Texas Veterans Health Care
System, TX, USA) with which the authors are affiliated.
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